HK Stock Market Move | KINTOR PHARMA-B(09939) surges over 12%, KX-826 announces two important clinical research data on WCHR 2026.

KINTOR PHARMA-B(09939) rose by over 12%, reaching a 9.2% increase at the time of publication, with a price of 2.73 Hong Kong dollars and a trading volume of 5.3576 million Hong Kong dollars. On the news front, Kantuo Pharmaceuticals announced that the self-developed and potentially pioneering KX-826 was presented at the 14th World Hair Research Conference (WCHR 2026) held in Seoul, South Korea from May 28 to 31. Two important clinical research data were released. KX-826 has shown excellent efficacy and safety in the treatment of male androgenic alopecia in Chinese adults, and the trial results were selected as outstanding posters at the conference. Currently, the company is actively pushing for the market approval application for KX-826. Once approved, KX-826 is expected to become a first-in-class topical innovative drug, filling the clinical new drug gap in the field of alopecia treatment and breaking the treatment pattern that has relied solely on minoxidil and finasteride for nearly 40 years.